首页> 美国卫生研究院文献>Drug Design Development and Therapy >Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process
【2h】

Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process

机译:通过使用超临界抗溶剂工艺开发醋酸甲孕甾酮固体分散体纳米颗粒以增强口服递送能力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In the present study, solid dispersion nanoparticles with a hydrophilic polymer and surfactant were developed using the supercritical antisolvent (SAS) process to improve the dissolution and oral absorption of megestrol acetate. The physicochemical properties of the megestrol acetate solid dispersion nanoparticles were characterized using scanning electron microscopy, differential scanning calorimetry, powder X-ray diffraction, and a particle-size analyzer. The dissolution and oral bioavailability of the nanoparticles were also evaluated in rats. The mean particle size of all solid dispersion nanoparticles that were prepared was <500 nm. Powder X-ray diffraction and differential scanning calorimetry measurements showed that megestrol acetate was present in an amorphous or molecular dispersion state within the solid dispersion nanoparticles. Hydroxypropylmethyl cellulose (HPMC) solid dispersion nanoparticles significantly increased the maximum dissolution when compared with polyvinylpyrrolidone K30 solid dispersion nanoparticles. The extent and rate of dissolution of megestrol acetate increased after the addition of a surfactant into the HPMC solid dispersion nanoparticles. The most effective surfactant was Ryoto sugar ester L1695, followed by D-α-tocopheryl polyethylene glycol 1000 succinate. In this study, the solid dispersion nanoparticles with a drug:HPMC:Ryoto sugar ester L1695 ratio of 1:2:1 showed >95% rapid dissolution within 30 minutes, in addition to good oral bioavailability, with approximately 4.0- and 5.5-fold higher area under the curve (0–24 hours) and maximum concentration, respectively, than raw megestrol acetate powder. These results suggest that the preparation of megestrol acetate solid dispersion nanoparticles using the supercritical antisolvent process is a promising approach to improve the dissolution and absorption properties of megestrol acetate.
机译:在本研究中,使用超临界抗溶剂(SAS)工艺开发了具有亲水性聚合物和表面活性剂的固体分散纳米颗粒,以改善乙酸孕甾酮的溶解和口服吸收。使用扫描电子显微镜,差示扫描量热法,粉末X射线衍射和粒度分析仪表征乙酸孕甾酮固形分散体纳米颗粒的理化性质。还评估了大鼠中纳米颗粒的溶出度和口服生物利用度。所制备的所有固体分散体纳米颗粒的平均粒度为<500nm。粉末X射线衍射和差示扫描量热法测量表明,乙酸孕甾酮以无定形或分子分散状态存在于固体分散体纳米颗粒中。与聚乙烯吡咯烷酮K30固体分散体纳米颗粒相比,羟丙基甲基纤维素(HPMC)固体分散体纳米颗粒显着增加了最大溶解度。向HPMC固体分散体纳米颗粒中添加表面活性剂后,乙酸孕甾酮的溶解程度和溶解速率增加。最有效的表面活性剂是Ryoto糖酯L1​​695,其次是D-α-生育酚聚乙二醇1000琥珀酸酯。在这项研究中,药物:HPMC:Ryoto糖酯L1​​695比为1:2:1的固体分散纳米颗粒在30分钟内快速溶出> 95%,此外还具有良好的口服生物利用度,约为4.0和5.5倍曲线下的面积(0-24小时)和最大浓度分别比未加工的乙酸孕甾酮粉高。这些结果表明,使用超临界抗溶剂法制备乙酸孕甾醇固体分散体纳米颗粒是改善乙酸孕甾醇的溶解和吸收性能的有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号